Plain-English translation of NCT06692738 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large global trial testing a new immunotherapy medication called to see if it works better than the standard treatment () for advanced squamous lung cancer. All participants will receive chemotherapy along with either the new medication or the standard medication. Researchers want to learn which treatment helps patients live longer and has fewer side effects.
Many patients with advanced squamous lung cancer need better treatment options that work longer and are easier to tolerate. This medication is being studied because early research suggests it may help the immune system fight cancer more effectively than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or the standard medication, both combined with chemotherapy. You would receive chemotherapy infusions (through an IV) on a set schedule, along with your assigned immunotherapy medication given regularly as well. The study involves multiple visits to the hospital or clinic for treatment, blood tests, and scans to monitor how well the treatment is working. The total duration depends on how your cancer responds, but you would continue treatment as long as it is helping and you are tolerating it well.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States